MEDI 8852

Drug Profile

MEDI 8852

Alternative Names: MEDI8852

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Humabs BioMed
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 05 Apr 2017 MedImmune withdraws a phase II trial prior to enrollment due to company decision in Influenza-A virus infections (Combination therapy) in Sweden, Spain, Denmark, Latvia, Germany and Czech Republic (IV) (NCT03028909)
  • 01 Dec 2016 MedImmune completes a phase I/II trial in Influenza-A virus infections (Monotherapy, Combination therapy) in USA and South Africa (IV) (NCT02603952)
  • 08 Sep 2016 Phase-II clinical trials in Influenza-A virus infections (Monotherapy) in USA (IV) before September 2016 (AstraZeneca pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top